Keyphrases
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
26%
Acute Myeloid Leukemia
52%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
52%
Anemia
33%
Blood Transfusion
26%
Chemotherapy
33%
Chronic Myeloid Leukemia
52%
Clinical Characteristics
52%
COVID-19
36%
COVID-19 Pandemic
52%
Diagnostic Performance
61%
Diarrhea Morbidity
26%
Diffuse Large B-cell Lymphoma (DLBCL)
83%
Exosomal
52%
Febrile Neutropenia
39%
Hematological Malignancies
31%
Hematopoietic Cell Transplantation
26%
Hospitalization
54%
Human Telomerase Reverse Transcriptase (hTERT)
52%
Immunochemotherapy
36%
Intensive Chemotherapy
57%
Israel
34%
Israeli
83%
Italian Studies
52%
Italy
29%
Leukemia Patients
46%
Lymphoma Patients
69%
Midostaurin
52%
Multicenter Retrospective Study
35%
Multiple Myeloma
45%
Multiple Myeloma Patients
36%
Multivariate Analysis
27%
Novel Agents
26%
Obinutuzumab
52%
Paraproteinemia
26%
Patient Management
35%
Patients with Hematological Malignancies
31%
Positron Emission Tomography-computed Tomography (PET-CT)
37%
Prevalence Characteristics
28%
Real-world Experience
30%
Relapsed or Refractory
35%
Response to Therapy
30%
Retrospective Analysis
38%
Rituximab
59%
Romidepsin
26%
Second-generation Tyrosine Kinase Inhibitors
26%
Skin Biopsy
26%
Tertiary Care Hospital
65%
Thrombocytopenia
31%
Type 1 Diabetes Mellitus (T1DM)
26%
Medicine and Dentistry
Acute Myeloid Leukemia
52%
Allogeneic Stem Cell Transplantation
26%
Anemia
33%
Anthrax
26%
Anticoagulation
26%
Autologous Stem Cell Transplantation
26%
B-Cell Lymphoma
26%
Belantamab Mafodotin
26%
Biological Marker
26%
Biopsy
52%
Blood Transfusion
26%
Cancer Syndrome
26%
Cell Transplantation
26%
Chronic Myelogenous Leukemia
52%
COVID-19
52%
Cutaneous T Cell Lymphoma
26%
Diabetes Mellitus
26%
Diagnosis
68%
Diffuse Large B-Cell Lymphoma
79%
Disease
100%
Feces Culture
26%
Fluorodeoxyglucose F 18
52%
Graft Failure
26%
Hematologic Malignancy
52%
Hematopoietic Stem Cell
26%
Hereditary Nonpolyposis Colorectal Cancer
26%
Infection
36%
Infectious Complication
26%
Liver Transplantation
26%
Lung Cancer
26%
Midostaurin
26%
Multiple Myeloma
79%
Nanoparticle
26%
Non-Hodgkin Lymphoma
26%
Observational Study
26%
Overall Survival
43%
Paraproteinemia
26%
Patient Care
26%
Positron Emission Tomography
26%
Positron Emission Tomography-Computed Tomography
59%
Prevalence
29%
Pulmonary Infiltrate
26%
Quality of Life
26%
Retrospective Study
66%
Romidepsin
26%
Skin Biopsy
26%
Steroid Treatment
26%
Telomerase Reverse Transcriptase
52%
Thrombocytopenia
36%
Tyrosine-Kinase Inhibitor
31%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
20%
Anemia
26%
Anthrax
26%
Arterial Thromboembolism
10%
Atrial Fibrillation
26%
Belantamab Mafodotin
26%
Biological Marker
26%
Bleeding
10%
Bortezomib
26%
Chemotherapy
34%
Cohort Study
33%
Colon Cancer
26%
Cutaneous T Cell Lymphoma
26%
Diffuse Large B Cell Lymphoma
26%
Disease
69%
Disease Course
10%
Event Free Survival
18%
Fluorodeoxyglucose F 18
26%
Follicular Lymphoma
11%
Graft Failure
26%
Hematologic Malignancy
52%
Hereditary Nonpolyposis Colorectal Cancer
26%
Infection
60%
Lung Cancer
26%
Lung Infiltrate
26%
Malignant Neoplasm
19%
Midostaurin
26%
Mortality Rate
13%
Multiple Myeloma
83%
Neutropenia
26%
Nonhodgkin Lymphoma
26%
Obinutuzumab
52%
Observational Study
26%
Overall Survival
33%
Pandemic
26%
Peripheral Neuropathy
13%
Peripheral T Cell Lymphoma
22%
Peroneus Nerve Paralysis
26%
Progression Free Survival
27%
Remdesivir
17%
Remission
26%
Retrospective Study
39%
Rituximab
59%
Romidepsin
26%
Solid Lipid Nanoparticle
26%
Symptom
13%
T Cell Lymphoma
11%
Telomerase Reverse Transcriptase
52%
Thrombocytopenia
31%
Tumor Syndrome
26%